IN8bio Statistics
Total Valuation
IN8bio has a market cap or net worth of $45.88 million. The enterprise value is $29.50 million.
Market Cap | 45.88M |
Enterprise Value | 29.50M |
Important Dates
The next estimated earnings date is Friday, May 10, 2024, before market open.
Earnings Date | May 10, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
IN8bio has 43.29 million shares outstanding. The number of shares has increased by 42.43% in one year.
Shares Outstanding | 43.29M |
Shares Change (YoY) | +42.43% |
Shares Change (QoQ) | +9.79% |
Owned by Insiders (%) | 15.97% |
Owned by Institutions (%) | 37.38% |
Float | 24.46M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 1.84 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.57, with a Debt / Equity ratio of 0.20.
Current Ratio | 4.57 |
Quick Ratio | n/a |
Debt / Equity | 0.20 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -147.70% and return on invested capital (ROIC) is -100.59%.
Return on Equity (ROE) | -147.70% |
Return on Assets (ROA) | -105.00% |
Return on Capital (ROIC) | -100.59% |
Revenue Per Employee | n/a |
Profits Per Employee | -$967,968 |
Employee Count | 31 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -64.67% in the last 52 weeks. The beta is -0.01, so IN8bio's price volatility has been lower than the market average.
Beta (1Y) | -0.01 |
52-Week Price Change | -64.67% |
50-Day Moving Average | 1.13 |
200-Day Moving Average | 1.17 |
Relative Strength Index (RSI) | 46.31 |
Average Volume (30 Days) | 351,527 |
Short Selling Information
The latest short interest is 51,614, so 0.12% of the outstanding shares have been sold short.
Short Interest | 51,614 |
Short Previous Month | 84,747 |
Short % of Shares Out | 0.12% |
Short % of Float | 0.21% |
Short Ratio (days to cover) | 0.27 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -30.01M |
Pretax Income | -30.01M |
Net Income | -30.01M |
EBITDA | -27.51M |
EBIT | -30.01M |
Earnings Per Share (EPS) | -$1.00 |
Balance Sheet
The company has $21.28 million in cash and $4.89 million in debt, giving a net cash position of $16.39 million or $0.38 per share.
Cash & Cash Equivalents | 21.28M |
Total Debt | 4.89M |
Net Cash | 16.39M |
Net Cash Per Share | $0.38 |
Equity / Book Value | 24.94M |
Book Value Per Share | 0.58 |
Working Capital | 19.23M |
Cash Flow
In the last 12 months, operating cash flow was -$23.34 million and capital expenditures -$600,000, giving a free cash flow of -$23.94 million.
Operating Cash Flow | -23.34M |
Capital Expenditures | -600,000 |
Free Cash Flow | -23.94M |
FCF Per Share | -$0.80 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
IN8bio does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -42.43% |
Shareholder Yield | -42.43% |
Earnings Yield | -65.40% |
FCF Yield | -52.17% |
Analyst Forecast
The average price target for IN8bio is $8.63, which is 714.15% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $8.63 |
Price Target Difference | 714.15% |
Analyst Consensus | Strong Buy |
Analyst Count | 4 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 3 |